Fc工程化抗体在儿童B细胞前体急性淋巴细胞白血病靶向CD19免疫疗法中的应用前景
Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia.
作者信息
Kellner Christian, Peipp Matthias, Gramatzki Martin, Schrappe Martin, Schewe Denis M
机构信息
Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
出版信息
Oncoimmunology. 2018 Apr 9;7(8):e1448331. doi: 10.1080/2162402X.2018.1448331. eCollection 2018.
CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great potential. In light of recent preclinical and clinical data, perspectives of such antibodies designed for improved effectiveness in BCP-ALL are presented.
基于T细胞的CD19免疫疗法为小儿B细胞前体急性淋巴细胞白血病（BCP-ALL）的治疗开辟了新途径。然而，经Fc工程改造的CD19抗体也可能具有巨大潜力。鉴于最近的临床前和临床数据，本文介绍了这类旨在提高BCP-ALL治疗效果的抗体的前景。
Zotero 插件